Ibritumomab tiuxetan
- Generic Name
- Ibritumomab tiuxetan
- Brand Names
- Zevalin
- Drug Type
- Biotech
- CAS Number
- 206181-63-7
- Unique Ingredient Identifier
- 4Q52C550XK
- Background
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
- Indication
For treatment of non-Hodgkin's lymphoma
- Associated Conditions
- Follicular Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma Refractory, Relapsed follicular B-cell non-Hodgkin's lymphoma
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma, B-CellNon-Hodgkin's LymphomaLymphoma, Low-Grade
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT00220285
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkins Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193440
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
- Conditions
- Non-Hodgkins Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193505
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
- Conditions
- Lymphoma, Non-HodgkinBlood and Marrow Transplant (BMT)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT00186589
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma, Low-GradeLymphoma, Non-Hodgkin
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT00168727
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸Northwest Oncology and Hematology, Elk Grove Village, Illinois, United States
🇺🇸Medical Specialists of Fairfield, Fairfield, Connecticut, United States
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
- Conditions
- B-Cell Lymphoma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2006-09-08
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 75
- Registration Number
- NCT00138086
- Locations
- 🇫🇷
Institut Curie, Paris, France
🇫🇷Hématologie CHU de Lille, Lille, France
🇫🇷Hôpital Saint Louis, Paris, France
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00119730
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2006-09-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT00057343
- Locations
- 🇺🇸
Research Site, Wausau, Wisconsin, United States
🇺🇸Biogen Idec Incorporated, San Diego, California, United States
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
- Conditions
- LymphomaLeukemia
- Interventions
- Procedure: Allogeneic Stem Cell Transplantation
- First Posted Date
- 2002-11-08
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT00048737
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.